PD 0332991 is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. This compound is a highly specific inhibitor of cyclindependent kinase 4 (Cdk4) (IC50, 0.011 ¦Ìmol/L) and Cdk6 (IC50, 0.016 ¦Ìmol/L), having no activity against a panel of 36 additional protein kinases. Therapeutic doses of PD0332991 cause elimination of phospho-Rb and the proliferative marker Ki-67 in tumor tissue and downregulation of genes under the transcriptional control of E2F.

June 21, 2017

prudect name : PD 0332991 is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. This compound is a highly specific inhibitor of cyclindependent kinase 4 (Cdk4) (IC50, 0.011 ¦Ìmol/L) and Cdk6 (IC50, 0.016 ¦Ìmol/L), having no activity against a panel of 36 additional protein kinases.
Therapeutic doses of PD0332991 cause elimination of phospho-Rb and the proliferative marker Ki-67 in tumor tissue and downregulation of genes under the transcriptional control of E2F.
PD0332991

Synonyms: CAS NO: 571190-30-2 Molecular Formula: C₂₄H₂₉N₇O₂Molecular Weight: 447.53Purity: 98% minSolubility: In DMSOStorage: −20°C

web site: www.medchemexpress.com